Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Lorenz Bastian, Sonja Hänzelmann, Martin Neumann, Alina Hartmann, Thomas Burmeister, Stefan Schwartz, Walter Fiedler, MD, Mustafa Kondakci, MD, Andreas Viardot, Professor Dr, Folker Schneller, Christoph Faul, MD, Max S. Topp, MD, Sören Franzenburg, Andre Franke, Heiko Trautmann, PhD, Nicola Goekbuget, MD, Monika Brüggemann, MD, Claudia D Baldus, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143032

Published: 2020

Journal Articles

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Kai Rejeski, MD, Carolina Berger, Liv Jentzsch, Semjon Willier, MD, Viktoria Blumenberg, MD, Veit Buecklein, MD, Christoph Faul, MD, Christian Schmidt, MD, Michael von Bergwelt, MD PhD, Tobias Feuchtinger, MD, Wolfgang Bethge, MD, Francis A. Ayuk, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141833

Published: 2020

Journal Articles

Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span

Irene Marini, Jan Zlamal, Lisann Pelzel, Wolfgang Bethge, Christoph Faul, MD, Ursula Holzer, PD Dr. MD, Karina Althaus, Tamam Bakchoul, Prof. Dr.

Blood (2019) 134 (Supplement_1): 2346.

https://doi.org/10.1182/blood-2019-131725

Published: 2019

Journal Articles

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Blood (2018) 132 (Supplement 1): 660.

https://doi.org/10.1182/blood-2018-99-111954

Published: 2018

Journal Articles

CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial

Monika Szczepanowski, PhD, Johanna Richter, Britta Kehden, Matthias Ritgen, MD, Heiko Trautmann, PhD, Henrik Knecht, PhD, Mustafa Kondakci, MD, Christoph Faul, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2018-99-114673

Published: 2018

Journal Articles

Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab

Ralf C Bargou, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, MD, Max S. Topp, Qui Tran, Xinke Zhang, Nicola Goekbuget, MD

Blood (2018) 132 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2018-99-112259

Published: 2018

Journal Articles

Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months

Nicola Goekbuget, MD, Hervé Dombret, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, MD, Max S. Topp, Monika Brüggemann, Kate Taylor, MSc, Ralf Bargou, MD

Blood (2018) 132 (Supplement 1): 554.

https://doi.org/10.1182/blood-2018-99-111516

Published: 2018

Journal Articles

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Michaela Kotrova, MD PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2018-99-112844

Published: 2018

Journal Articles

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Monika Brüggemann, Joachim Beck, MD, Christoph Faul, MD, Christian Koenecke, MD, Heinz A. Horst, MD PhD, Mustafa Kondakci, MD, Doris M. Kraemer, MD, PhD, Christoph Lutz, MD, Bernd Spriewald, MD, Michael Starck, MD, Christoph Rollig, MD MSC, Matthias Stelljes, MD, Andreas Viardot, MD, Ralph Wäsch, Knut Wendelin, MD, Hubert Serve, Michael Kneba, MD, Dieter Hoelzer, MD PhD

Blood (2017) 130 (Supplement 1): 139.

https://doi.org/10.1182/blood.V130.Suppl_1.139.139

Published: 2017

Journal Articles

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT)

Francis A. Ayuk, MD, Dietrich W. Beelen, Prof. Dr. MD, Martin Bornhäuser, MD, Matthias Stelljes, Tajana Zabelina, MD, Jürgen Finke, Guido Kobbe, MD, Daniel Wolff, MD, Eva Maria Wagner, MD, Maximilian Christopeit, MD, Christoph Schmid, MD, Hellmut Ottinger, MD, Christoph Groth, MD, Christoph Faul, MD, Hartmut Bertz, MD, Elena Rachlis, MD, Christine Wolschke, MD, Nicolaus Kröger, MD, Wolfgang Bethge, MD

Blood (2016) 128 (22): 2304.

https://doi.org/10.1182/blood.V128.22.2304.2304

Published: 2016

Journal Articles

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Sebastian P. Haen, MD, Manfred Zierhut, MD, Nora Mirza, PhD, Christoph M. Simon, MD, Andreas Korn, MD, Christoph Faul, MD, Wichard Vogel, MD, Hans-Georg Rammensee, PhD, Lothar Kanz, MD, Wolfgang Bethge, MD

Blood (2016) 128 (22): 4620.

https://doi.org/10.1182/blood.V128.22.4620.4620

Published: 2016

Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD

Blood (2015) 126 (23): 680.

https://doi.org/10.1182/blood.V126.23.680.680

Published: 2015

Journal Articles

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Sebastian P. Haen, MD, Michael Schumm, DVM, Wichard Vogel, MD, Christoph Faul, MD, Rupert Handgretinger, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2013) 122 (21): 5475.

https://doi.org/10.1182/blood.V122.21.5475.5475

Published: 2013

Journal Articles

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Christoph Simon, Nora Mirza, Wolfgang A. Bethge, MD, Wichard Vogel, MD, Christoph Faul, MD, Hans-Georg Rammensee, Lothar Kanz, MD, Sebastian P. Haen, MD

Blood (2013) 122 (21): 2069.

https://doi.org/10.1182/blood.V122.21.2069.2069

Published: 2013

Journal Articles

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 2084.

https://doi.org/10.1182/blood.V122.21.2084.2084

Published: 2013

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 4538.

https://doi.org/10.1182/blood.V122.21.4538.4538

Published: 2013

Journal Articles

Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Blood (2013) 122 (21): 839.

https://doi.org/10.1182/blood.V122.21.839.839

Published: 2013

Journal Articles

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Dominik Schneidawind, MD, Sebastian Jendryssek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 4482.

https://doi.org/10.1182/blood.V120.21.4482.4482

Published: 2012

Journal Articles

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Sebastian P. Haen, Benjamin J Schmiedel, PhD, Nora Roth, Christoph Faul, MD, Robert Möhle, Marc Schmalzing, MD, Lothar Kanz, MD, Wichard Vogel, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 1421.

https://doi.org/10.1182/blood.V120.21.1421.1421

Published: 2012

NARROW

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial

Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab

Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT)

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only